Are ARBs or ACE inhibitors preferred for nephropathy in diabetes?
Metadata[+] Show full item record
Angiotensin receptor blockers (ARBs) have been shown to reduce the progression of nephropathy in several consistent studies. While ACE inhibitors have not been as well studied for the endpoint of nephropathy, patients with nephropathy exhibit reduced mortality when treated with an ACE inhibitor (strength of recommendation: A, based on randomized controlled trials).
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.